UPDATE: Halozyme Reports Clinical Hold of PEGPH20 Pancreatic Cancer Trial Amid Voluntary Halt
April 09, 2014 at 08:07 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the United States Food and Drug Administration (FDA) informed the ...